ukatekexo.wordpress.com
But GTx (Nasdaq: GTXI) is “exploring multiple as to how the sales force will be according to GTx CEOMitchell Steiner. He wasn’t sure if the compan y would roll out its own sale team or contract with a team througha “The most risky part of building the team is the actuaol sales people on the pavement,” Steinerf said in a conference call. “So, we want to spendc as much money as up front to better ensure the success of thesalews force.
Steiner said the higher-level marketing staff have all been hireed and are working on the commercialization plan for the new But the company is now hard at work puttinfg together the sales materials that will be needed should the drug get theFDA nod. Accordin to its most recent filing withthe SEC, expensea related to increased personnel, medical education and marketing for the toremifene drug family rose 51 percent from $4.3 milliomn in 2008’s first quarter to $6.5 million in this year’sx first quarter. The Memphis-based pharmaceutical compangy expects to get word from the FDAon Oct. 30. The company reported $11.3 million in net losses for the firsf three monthsof 2009.
That figurwe is 11 percent betterd thanthe $12.7 milliobn the company reported in last year’s first Revenues fell 20 percent from $4.5 million in 2008 to $3.6 millio this quarter. However, sales of the company’s treatment for metastatic breasty cancer, rose from $257,00o0 last quarter to $759,000 in this year’sa first quarter. The company’s stock rose slightly in afternoon tradinhgto $9.
68 per up less than 1 percent from Friday’s close of GTx is a biopharmaceutical company that seeke to discover, develop and commercialize small molecules that selectiveluy target hormone pathways to treat cancer, osteoporosie and bone loss, muscle wasting and othee serious medical conditions.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment